Provocative Biotech Exposition Reveals Significant Advancements in Stem Cell Research, Immunotherapy, Targeted …

STAMFORD, CT--(Marketwire - Oct 3, 2012) - Noble Financial Capital Markets (Noble) announced today that it has released a full high definition video catalog of its Life Sciences Exposition, BIOX, an investor exposition that was held at the University of Connecticut in Stamford, CT on September 24-25, 2012. In addition to the participation of more than two dozen biotechnology companies, the event featured world renowned key opinion leaders Dr. Mark Noble (University of Rochester), R. Phil Greenberg (Fred Hutchinson Cancer Research Center), Dr. Jeffrey Infante (Sarah Cannon Research Institute), and Dr. Charles Vacanti (Harvard Medical School).

Opening remarks were provided by Dr. Sharon White, Director of the UCONN Stamford campus and Richard Blumenthal, United States Senator for Connecticut. "Washington is dysfunctional and broken," Blumenthal said. "The good news is that scientific advancements and research offer a real opportunity to reach across the aisle; this is an area that should inspire bipartisan cooperation."

Overwhelmingly, the message coming from the Exposition was one of encouragement that we are making great strides in the effective treatment of catastrophic disease, in particular cancers. Determining genetic differences in tumors, which has posed challenges for biomarkers, has improved significantly with advancements in molecular biology. Novel and approved targeted agents is the next rationale step in matching tumor types with appropriate therapies; a developmental step that large pharmaceutical companies have already taken.

Dr. Noble, who led a panel moderated by Noble Financial Senior Analyst, Nathan Cali and consisting of executives from Cytomedix, Cytori, MediStem, Mesoblast and NeoStem, expressed optimism that stem cell therapy will continue to grow exponentially. "Stem cells are a natural cascade offering the potential to treat significant unmet medical needs," he said."The path to better cancer treatment comes from a clearer understanding of cancer stem cell biology."

Rahul Jasuja, Noble Financial's Managing Director of Biotechnology Research moderated the panel which focused on immunotherapy and vaccines. Executives from Argos, Galena, Inovio, NewLink and Prima Biomed joined Dr. Phil Greenberg (referred to as Dr. T-Cell) to debate the challenges and advancements in the understanding of how the immune system is suppressed by cancer cells. While a consensus was not reached in terms of specific methods to harness the immune system, all agreed that the next generation of immunotherapy approaches will aim to "realign" the immune system to destroy cancer.

Jules Msing, Chairman of Noble's Scientific Advisory Board and the former head of Global Drug Licensing for Johnson & Johnson addressed attendees at the opening session and again on day two of the Exposition. "The hope is great that all of the technologies and innovations that will be discussed here today will have a huge impact on healthcare around the world," he said. "This, however, is reliant on the underlying assumption that society's acceptance of healthcare innovation and our willingness to invest in it will continue into the future," he added. Msings' presentation to life science corporate executives centered on the question of why some biotech companies can attract the attention of large pharma while others cannot and why many licensing executives in large pharma are unable to convince their R&D groups or executive committees to make substantial investments in these companies. Mr. Msing negotiated deals with various companies such as Vertex Pharmaceuticals, Genentech, OSI Pharmaceuticals, Bristol Meyers Squibb, CTI Inc., Regeneron, Alkermes, Enzon Pharmaceuticals, GTx Inc, Alliance Pharmaceuticals, Allos Therapeutics, Somatogen, Morphotek, Edison Pharmaceuticals, etc.

Based upon the success of this event, Noble Financial has begun planning its second Life Sciences Exposition for the fall of 2013. Noble's Ninth Annual large-format investor conference that will feature 150 public companies is scheduled for January 22-23, 2013 at the Hard Rock Hotel in Fort Lauderdale.

Complete HDVideo webcast catalog available at:

Provocative Biotech Exposition Reveals Significant Advancements in Stem Cell Research, Immunotherapy, Targeted ...

Related Post